124 results about "Non peptide" patented technology

Invented is a method of treating degenerative diseases / injuries, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.

The in vitro polymerization of silica, silicone, non-silicon metalloid-oxane and metallo-oxane polymer networks, by combining a catalyst and a substrate to polymerize the substrate to form silica, polysiloxanes, polymetalloid-oxanes polymetallo-oxanes (metal oxides), polyorganometalloid oxanes, polyorganometallo oxanes, and the polyhydrido derivatives thereof, at about neutral pH. The nanostructure-directing catalysts have a nucleophilic functionality and a hydrogen-bonding acceptor group, and include: silicateins, enzymes that work by a mechanism functionally related to that of the silicateins; self-assembling peptides related to those synthesized and demonstrated capable of acting as biomimetic substitutes for the silicateins; non-peptide-based synthetic polymers containing a nucleophilic group and a hydrogen bonding amine such that the polymer functions by a mechanism of action related to that of the silicateins; materials having such chemical functionality as a nucleophilic group and or a hydrogen bonding amine which, acting in concert with nanoconfinement and or chemical functionality of the surface or matrix to which the functionality is attached, acts catalytically by a mechanism related to that of the silicateins; and small-molecule non-polymeric biomimetic catalysts that operate by the same mechanism as silicateins. The substrate is selected from groups consisting of silicon alkoxides, non-silicon metalloid alkoxides or metal alkoxides, and any organic, organometallic or hydrido derivatives of the foregoing; inorganic and organic oxygen-containing chelates of silicon, non-silicon metalloids or metals and any organic, organometallic or hydrido derivatives of the foregoing; and inorganic and organic esters of the hydoxides of silicon, non-silicon metalloids or metals and any organic, organometallic or hydrido derivatives of the foregoing; and inorganic and organic hydolyzable salts, complexes or conjugates of the hydroxides of silicon, non-silicon metalloids or metals and any organic, organometallic and hydrido derivates of the foregoing.

This invention relates to macrocyclic chelants comprised of one or two heteroatom-containing bridges, compositions containing them and their use in medicine, particularly in diagnostic imaging and radiotherapy. This invention relates especially to the use of metal chelates of the macrocyclic chelants as metallopharmaceuticals in Magnetic Resonance Imaging (MRI) and radiopharmaceuticals. This invention also relates to macrocyclic chelants as bifunctional chelating agents (BFC's) for the labeling of biologically active targeting molecules such as proteins, peptides, peptidomimetics, and non-peptide receptor ligands, with metal ions and radioisotopes.